Moogene Medi

Founded in 2016, Moogene Medi has grown as a nano-medicine specialist whose core competency lies in its LNP drug-delivery platform.

The company can load gene-editing materials (CRISPR/Cas9), protein therapeutics, and mRNA onto LNPs for targeted in-vivo delivery, and holds proprietary LNP composition patents that circumvent those held by global pharma majors.

Its business is structured around two pillars: the cosmetic raw materials and dermatological devices segment, which contributed approximately 73% of revenues in FY2024, and the LNP-based pharmaceutical CDMO segment, which accounted for roughly 27%.

The R&D pipeline spans the colorectal cancer candidate DREC-21, the pancreatic cancer candidate PDAC-11, the topical hair-loss therapy HUTERA, a type-2 diabetes treatment, an mRNA cancer vaccine, and rare-disease therapeutics.

HUTERA is differentiated from oral formulations by its nano-liposome microbubb structure containing finasteride or dutasteride, enabling follicle-cell delivery through simple scalp application.

In terms of competition, domestic LNP players include Yuhan, Enhanced Bio, and Inventage Lab, while globally Moderna, Pfizer/BioNTech dominate LNP know-how, leaving intense competitive pressure. Moogene Medi offsets its small scale via proprietary composition patents and an established GMP facility as a CDMO base.

Headquartered in Pangyo, Seongnam, the company operates with a staff in the mid-30s, reflecting its research-focused, small-enterprise character.

In FY2024 (standalone basis), Moogene Medi's financials deteriorated across the board. Revenue declined 16.4% YoY, operating loss widened by 21.3%, and net loss surged a steep 141.8%, indicating a broad-based erosion of financial health.

The revenue shortfall is attributed to weakness in the core cosmetic raw materials and dermatological devices segment, compounded by consistently rising R&D expenditures—a structural feature of a fixed-cost-heavy research organisation.

As of 7 June 2026, the stock stood at KRW 2,085, unchanged from the prior session, with market capitalisation negligible in absolute terms. Daily trading value of approximately KRW 9.23 million underscores extreme illiquidity and constrained price-discovery.

KONEX's limited institutional participation means trading is dominated by retail investors, further amplifying price volatility risk.

The LNP-based pharmaceutical CDMO segment accounted for roughly 27% of FY2024 revenue, but delays in commercialising clinical-stage pipeline assets make rapid CDMO revenue growth challenging near term.

Structurally subdued trading activity across the KONEX market adds a further layer of constraint to price formation for this stock.

Moogene Medi's growth trajectory hinges on two key axes.

First is the pace of clinical progression for the topical hair-loss treatment HUTERA; the company is actively pursuing IND approval, and success in this competitive market—where novel mechanisms like oligo RNAi candidates are advancing—could establish a meaningful commercial foothold.

Second is the order intake of its mRNA-LNP CDMO business; with GMP capacity in place, landing external manufacturing contracts in a structurally expanding global mRNA drug market would visibly lift the CDMO revenue share.

However, competing against global-scale CDMO operators on price and capacity is a near-term constraint. The oncology pipeline (DREC-21, PDAC-11) is expected to take considerable time before clinical entry and is therefore a medium-to-long-term catalyst.

Given that the loss-widening trend driven by R&D costs is unlikely to reverse quickly, external fundraising or technology licensing-out deals emerge as pivotal variables for financial stability.